Pyrido[2,3-b]pyrazin-7-ylboronic acid, pinacol ester
Product Information
Molecular Formula
C13H16BN3O2
Molecular Weight
257.1
Description
Pyrido[2,3-b]pyrazin-7-ylboronic acid, pinacol ester is an indispensable compound in the realm of the biomedical sector. Its utilization revolves around the exploration of revolutionary pharmaceutical solutions, transcending the boundaries of maladies comprising cancer, diabetes, and neurodegenerative conditions. Notably, this ester derivative presents a remarkable amplitude of improved reliability, solubility, and bioavailability, serving as a promising adjunct in forging proficient drug formulation and dispensation mechanisms.
Synonyms
7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrido[2,3-b]pyrazine; 1210047-44-1; Pyrido[2,3-b]pyrazin-7-ylboronicacidpinacolester; 7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDO[2,3-B]PYRAZINE; Pyrido[2,3-b]pyrazine-7-boronicacid,pinacolester; Pyrido[2,3-b]pyrazin-7-ylboronicacid,pinacolester
IUPAC Name
7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrido[2,3-b]pyrazine
SMILES
B1(OC(C(O1)(C)C)(C)C)C2=CC3=NC=CN=C3N=C2
InChI
InChI=1S/C13H16BN3O2/c1-12(2)13(3,4)19-14(18-12)9-7-10-11(17-8-9)16-6-5-15-10/h5-8H,1-4H3
InChI Key
QLYMAIYXJXENHJ-UHFFFAOYSA-N
Melting Point
167-172 °C
Flash Point
Not applicable
Purity
95%
Storage
2-8°C
Safety Information
Hazards
H315 - H319 - H335
Precautionary Statement
P302 + P352 - P305 + P351 + P338
Computed Properties
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
1
Exact Mass
257.1335569 g/mol
Monoisotopic Mass
257.1335569 g/mol
Topological Polar Surface Area
57.1Ų
Heavy Atom Count
19
Formal Charge
0
Complexity
335
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| WO-2021249913-A9 | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer | 2020-06-09 |
| US-2021078975-A1 | Fused cyclic urea derivatives as crhr2 antagonist | 2018-04-09 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | 2015-04-17 |
| US-2016304517-A1 | Tricyclic modulators of tnf signaling | 2015-04-17 |
| US-2018179198-A1 | Tricyclic modulators of tnf signaling | 2015-04-17 |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | 2015-04-17 |
| US-2014179676-A1 | Heterocyclic nuclear hormone receptor modulators | 2012-12-21 |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | 2012-12-21 |
| US-2014045814-A1 | Pyrazine derivatives as fgfr inhibitors | 2012-08-10 |
| US-2016280713-A1 | Pyrazine derivatives as fgfr inhibitors | 2012-08-10 |
